# 1 Seroprevalence and associated factors of maternal

# 2 cytomegalovirus in Southern Ethiopia

- <sup>3</sup> \*Mengistu Hailemariam Zenebe<sup>1, 2, 3</sup>, Zeleke Mekonnen<sup>2</sup>, Eskindir Loha<sup>4, 5</sup> and Elizaveta
- 4 Padalko<sup>3, 6</sup>
- <sup>5</sup> <sup>1</sup>School of Medical Laboratory Sciences, Hawassa University college of Medicine and Health
- 6 Sceinces, Hawassa, Ethiopia
- <sup>2</sup> School of Medical Laboratory Sciences, Jimma University Institute of Health
- 8 Jimma University, Jimma, Ethiopia
- <sup>3</sup> Department of Diagnostic Sciences, Ghent University, Ghent, Belgium
- <sup>4</sup>Centre for International Health, University of Bergen, Bergen, Norway
- <sup>5</sup> Chr. Michelson Institute, Bergen, Norway
- <sup>6</sup> Laboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium
- 13
- 14 \*Corresponding author, mailing address: School of laboratory science Hawassa University

P.o.Box=1560, Hawassa, Ethiopia, Phone: (+251913641103), E-mail address:
 <u>mengemariamzenebe@gmail.com</u>

- 17
- 18

## 19 Abstract

Introduction: Cytomegalovirus (CMV) is the most common infection during pregnancy that poses the risk of congenital CMV infections (cCMV) worldwide. The aim of this study was to assess the seroprevalence and associated factors of CMV among pregnant women in Southern Ethiopia.

Method: A cross-sectional study was conducted on consecutive women attending the delivery ward at Hawassa comprehensive and specialized hospital. Blood samples collected at the time of delivery were tested for CMV IgG and IgM using ELISA. Study participants responded to a questionnaire about obstetric history and socio-demographic characteristics. Data analysis was performed using SPSS version 20.0 software. Chi-square, bivariable and multivariable logistic regression were used to identify characteristics independently associated with the sero-status of CMV.

**Results**: Seropositivity for CMV IgM antibodies was 8.2% (49/600) (95% CI: 6 -10.5%), whereas the CMV IgG was 88.6% (532/600), (95% CI: 89.5 - 94.0%). Seroprevalence was higher in women of older age, currently unmarried and having nursery schooled children. Moreover CMV seropositivity was significantly associated with any of detected curable STIs. Seroprevalence was not significantly related to previous adverse pregnancy outcome, gravidity, being a child day care occupant mother, and birth weight of the newborn.

Conclusion: In the present study, we identified a high rate of CMV IgM seropositivity among pregnant women in southern Ethiopia. Given that there is no existing CMV diagnosis, special attention should be designed for pregnant women in parallel to the existing antenatal care facility. Besides, training health care professionals will support awareness conception among pregnant women concerning the sequels of CMV infection during pregnancy.

# 42 Key questions

43

#### 44 What is already known?

- Cytomegalovirus is the most common infection during pregnancy that can cause
   congenital CMV infections and known to cause long-term sequelae including
   sensorineural hearing loss of the developing fetus.
- However, data on maternal CMV infection lacking in Ethiopia besides there is no
   maternal CMV diagnostics and screening service for pregnant women.
- 50 What are the new findings?
- A high prevalence 8.3% of CMV IgM and 88.6% of CMV IgG documented.
- Seroprevalence associated with older age women, currently unmarried and having
   nursery schooled children in the household. Also CMV seropositivity was significantly
   associated with any of detected curable STIs.
- 55 What do the new findings imply?
- Known that there is no existing maternal CMV screening in Ethiopia, understanding the
   burden and the effect of maternal CMV infection will offer important information to the
   health care providers to prevent a sequel to the developing fetus.
- The current study provides valuable information on the associated factors with maternal
   CMV infection hence, training health care professionals will support awareness
   conception among pregnant women concerning the sequels for CMV infection during
   pregnancy.

# 63 Introduction

64 Cytomegalovirus (CMV) is the most common infection during pregnancy that poses the risk of 65 congenital CMV infections (cCMV) worldwide.(1) In immunocompetent hosts, primary CMV 66 infection may be asymptomatic or may cause mild self-limiting disease with fever, headaches, 67 and myalgia and after primary infection the virus remains latent. Latency following a primary 68 infection may relapse by periodic reactivations that give rise to recurrent infections later in life 69 when the body immunity is suppressed.(2)

CMV infection or reactivation during pregnancy is mostly asymptomatic, however may lead to fetal infection and cCMV syndromes.(3) Congenital CMV infection of the fetus of mothers having pre-existing anti-CMV antibodies is also possible due to risk of reactivation or reinfection with a different strain of CMV during pregnancy.(4) Therefore unlike previous perception the high maternal CMV seroprevalence in developing countries like Ethiopia does not eliminate the threat of cCMV infection of the newborn. Worldwide cCMV following nonprimary maternal infections is more common in individuals of lower socioeconomic background.(5)

So far studies have shown maternal seropositivity rates of previous infection ranging from low (50 to 70%) in developed countries, to high (> $\Box$ 70%) in developing countries.(1) Presently, data on the prevalence of maternal CMV and associated risk factors are scanty in Ethiopia. The only available study conducted in Ethiopia had reported the prevalence of 15.5% for IgM and 88.6% for CMV IgG.(6)

In Africa the highest prevalence of CMV IgG was estimated ranging from 72 – 97.5% (7, 8) and
of CMV IgM antibodies ranging from 0-15.5%.(9) However, for several reasons CMV infection

84 among pregnant women in Africa have been overlooked.(10) One of the main reasons for 85 inattention is the perception that being infected in early childhood endures immunity for subsequent infection, so maternal reactivation or reinfection during pregnancy is unlikely to 86 87 cause severe congenital infection.(11) However, in pregnant women the immune system is somehow suppressed. So ignoring maternal CMV and the subsequent effect of cCMV infection 88 in Africa is short-sighted; furthermore, the possible confounding effects of HIV infection, 89 90 malnutrition, tuberculosis, and a general higher disease burden of the continent must be taken 91 into account.(12)

The objective of the study was to assess the seroprevalence of CMV among pregnant women and determine associated factors in Southern Ethiopia. Information about maternal the prevalence of CMV and associated risk factors is almost absent in Ethiopia and this study was the first in the southern region. We hope the study will attract health care professional attention and improve antenatal care in this domain. In the meantime it will generate awareness to the community, mainly pregnant women, regarding the consequence of CMV during pregnancy in Ethiopia.

# 98 Methodology

## 99 Study setting and recruitment

From August to October 2020, a cross-sectional study was conducted among pregnant women who came for delivery in the obstetrics ward at Hawassa University Comprehensive and Specialized Hospital (HU-CSH), Ethiopia. Interrelated with the first phase of this project, where the initial 350 pregnant women had been tested for curable STI (*C. trachomatis*, *N. gonorrhoeae* and *T. vaginalis*) using GeneXpert (Xpert CT/NG and Xpert TV assays, Cepheid, Sunnyvale,

California, USA), our manuscript being submitted and under review (manuscript number PONED-20-37668). In this second phase of the study, by including those initially enrolled 350
pregnant women, a total of 600 consecutively enrolled pregnant women were participated.
Pregnant women were recruited upon delivery regardless of gestational age. A midwife at the
obstetric ward provided general information about the study to all pregnant women before
recruitment.

### 111 Socio-demographic, obstetric and behavioral data

Trained midwife at the obstetric ward provided general information about the study to pregnant women who came for delivery. Pregnant women agreeing to join in the study were interviewed using a structured questionnaire translated in Amharic, the language spoken by most people in the study area. The translated questionnaire was pre-tested on random mother at antenatal clinic to ensure the validity and feasibility of the questions as conducted in similar studies. Information related to socio-demographic characteristics (e.g., age, marital status, and educational level), obstetric history, and behavioral data were collected.

#### **119** Sample collection and storage

The midwife-nurse aseptically collected a 3 ml blood sample from each subject. The collected samples were transported to the HU-CMHS microbiology laboratory within 12 hours of collection and the processed serums stored at  $-20 \text{ C}^0$  until analysis.

#### 123 Laboratory methods

Testing was performed in Belgium, Ghent University hospital, department of laboratory 124 125 medicine, using a commercially available enzyme immunoassay (ELISA) kit (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany) for anti-CMV IgG and IgM according to 126 127 the manufacturer's instructions. Results were evaluated semi-quantitatively by calculating a ratio of the extinction value of the patient sample over the extinction value of the calibrator optical 128 Seropositivity was defined according to the guidelines given by the 129 density at 450 nm. 130 manufacturer, CMV negative when the ratio cut off value was < 0.8, borderline between 0.8 and 1.1, and positive if >1.1 for both IgG and IgM. 131

### 132 **Ethical considerations**

Ethical approval from all of the appropriate institutional review boards was obtained. The ethics 133 (CMHS/283/2012). 134 review committee of Hawassa University Jimma University 135 (IHRPGD/458/2020), National Health Research Ethics Review Committee (SRA/14.1/ 144483/2020) Ethiopia, and Ghent University (PA2019-038/BC-08458) Belgium, approved the 136 study. All participants provided written, informed consent for study participation. 137

#### 138 **Data analysis**

Descriptive statistics were used to characterize the socio-demographic and obstetric and medical characteristics of the participants. We evaluated the seroprevalence of CMV and associated factors using a logistic regression model. Bivariate comparisons using Chi-square or Fisher's exact test where suitable were used to examine the relationships between participant characteristics and CMV test result. Finally, multivariable logistic regression was used to

identify characteristics independently associated with sero-status of CMV and adjusting for other factors. Variables with a significant level of  $\leq 0.2$  were included in the final model. P value < 0.05 is considered statistically significant. SPSS software version 20.0 (SPSS Inc. Chicago, IL, USA) was used for all analyses.

### 148 **Results**

Six hundred pregnant women were assessed for seroprevalence of CMV. The mean of maternal 149 age was  $27.0 \pm (SD)$  5.2, with a ranging between 17 and 41. More than one-third of the study 150 participant were under the age of 25. About one-fourth of the women were Primigravida. Out of 151 152 the 600 participant 84 (14%) were currently unmarried, 475 (79.2%) were residing in urban 153 setting, 377 (62%) were above or at secondary level of education. Forty-eight (8%) of the newborns were under-weighted (<2.5 Kg), and 64 (10%) of the births were preterm. Regarding 154 155 STIs test result, 51 (14.6%) pregnant women were tested positive for any of curable STIs (Table 1). 156

In this study, around 96% of mothers had no knowledge of congenitally transmitted infection or the associated risks in pregnancy and about 9% of them had previous adverse pregnancy outcome. The chi- squire analysis shown that, seropositivity for CMV IgM significantly associated (p<0.05) with marital status, gestational age, having nursery school baby in the household, sharing a cup with children and having any of detected curable STIs. However, there was no significant association with birth weight, gravidity and having previous adverse pregnancy outcome i.e. preterm birth, stillbirths and early neonatal death (Table 1).

#### 164 Table 1 Maternal characteristics and associated factor with CMV IgM seropositivity in

#### 165 Southern Ethiopia

Characteristics	Total (N=600)	IgM-Positive	IgM-Negative	p-value
	n (%)	(n=49) n (%)	(n=551) n (%)	
Age of mothers (years)				
<25	233 (38.8)	14 (28.6)	219 (39.7)	0.148
25-29	162 (27.0)	14 (28.6)	148 (26.9)	
30- 35	170 (28.3)	15 (30.6)	155 (28.1)	
>35	35 (5.8)	6(12.2)	29 (5.3)	
Marital status				
Married	516 (86.0)	37 (75.5)	479 (86.9)	
Currently unmarried	84 (14.0)	12 (24.5)	72 (13.1)	0.027
Residence				
Urban	475 (79.2)	44 (89.8)	431 (78.2)	0.056
Rural	125 (20.8)	5 (10.2)	120 (21.8)	
ANC follow up during pregnancy				
Yes	576 (96.0)	48 (98.0)	528 (95.8)	
no	24 (4.0)	1 (2.0)	23 (4.2)	0.712
Employed as daycare worker				
Yes	40 (6.7)	6 (12.2)	34 (6.2)	0.126
No	560 (93.3)	43 (87.8)	517 (93.8)	
Employed as health care				
Yes	32 (5.3)	6 (12.2)	26 (4.7)	0.055
no	568 (94.7)	43 (87.8)	525 (95.3)	
Education				
Primary and below	223 (37.2)	13 (26.5)	210 (38.1)	0.108

Secondary and above	377 (62.8)	36 (73.5)	341 (61.9)	
Gestational age				
Term	536 (89.3)	36 (73.5)	500 (90.7)	
Preterm	64 (10.7)	13 (26.5)	51 (9.3)	<0.001
Birth weight				
<2.5 Kg	48 (8.0)	3 (6.1)	45 (8.2)	0.789
>2.5 Kg	552 (92.0)	46 (93.9)	506 (91.8)	
Gravidity				
Primigravida	147 (24.5)	14 (28.6)	133 (24.1)	0.489
Multigravida	453(75.5)	35 (71.4)	418 (75.9)	
Previous adverse pregnancy outcome *				
Yes	39 (8.6)	2 (5.7)	37 (8.9)	0.756
No	414 (91.4)	33 (94.3)	381 (91.1)	
Knowledge on congenitally transmitted				
infections				
Yes	25 (4.2)	1 (2.0)	24 (4.4)	
No	575 (95.8)	48 (98.0)	527 (95.6)	0.712
Under-five children in the household				
Yes	396 (66.0)	31 (63.3)	365 (66.2)	0.673
no	204 (43.0)	18 (36.7)	186 (33.8)	
Daycare or Nursery school baby in the				
household				
Yes	259 (43.2)	31 (63.3)	228 (41.4)	0.003
no	341 (56.8)	18 (36.7)	323 (58.6)	
Sharing feeding cup with children				
Yes	107 (17.8)	14 (28.6)	93 (16.9)	0.040
no	493 (82.2)	35 (71.4)	458 (83.1)	

Sharing eating utensil with children				
Yes	88 (14.7)	8 (16.3)	80 (14.5)	0.732
No	512 (85.3)	41 (83.7)	471 (85.5)	
Sharing teeth brush with children				
Yes	42 (7.0)	3 (6.1)	39 (7.1)	0.999
No	558 (93.0)	46 (93.9)	512 (92.9)	
N.gonorrhoeae detected (n=350)				
Yes	15 (4.3)	3 (10.0)	12 (3.8)	0.128
No	333 (95.7)	27 (90.0)	306 (96.2)	
C. trachomatis detected (n=350)				
Yes	29 (8.3)	5 (16.7)	24 (7.5)	0.089
No	319 (91.7)	25 (83.3)	294 (92.5)	
T. vaginalis detected (n=350)				
Yes	11 (3.1)	2 (6.9)	9 (2.8)	0.241
No	335 (96.8)	27 (93.1)	308 (97.2)	
Any of curable STI detected (n=350)				
Yes	51 (14.6)	10 (33.3)	41 (12.8)	0.005
No	299 (85.4)	20 (66.7)	279 (87.2)	

166

167

\*previous adverse pregnancy includes; early neonatal death, stillbirth and preterm birth : STI; Sexually
 transmitted infections

### 170 Seroprevalence

Seropositivity of CMV IgM antibodies was 8.2% (49/600) (95% CI: 6 -10.5%), whereas
seroprevalence of CMV IgG was 88.6% (532/600), (95% CI: 89.5 - 94.0%). Of 532 CMV IgG
positive women, 483 (80.4%) were negative for IgM. Among all pregnant women, 68 (11.4%)

- 174 were tested negative for both anti-CMV IgG and IgM, and none showed anti-CMV IgG
- 175 negativity but IgM positivity (Table 2).

	Anti CMV IgG anti	Anti CMV IgG antibody n (%)		
Anti CMV IgM antibody	Positive	Negative		
Positive	49 (8.2)	0 (0)	49 (8.2)	
Negative	483 (80.4)	68(11.4)	551 (91.8)	
Total	532 (88.6)	68(11.4)	600	

#### 176 Table 2 Cytomegalovirus IgM and IgG test result of pregnant women

### 177 CMV seropositivity and associated factors

In bivariable analysis, seropositivity was more common in elder women (>35) compared to the youngest age group, in women who were currently unmarried, giving preterm birth, sharing a feeding cup with children or having nursery schooled children. Moreover women were positive for any of curable STIs also had a higher seroprevalence of CMV compared to those negative for STIs (Table 3).

Furthermore, in multivariable logistic regression maternal IgM seropositivity was associated with elder age groups (AOR = 4.9, 95% CI: 1.0-23.4), currently unmarried women (AOR = 3.8, 95% CI: 1.7-7.9), preterm birth (AOR = 3.9, 95% CI: 1.5-10.3) and having nursery schooled children (AOR = 2.7, 95% CI: 1.1-6.4). Mothers with STIs has an association with seroprevalence (AOR = 4.1, 95% CI: 1.6-10.6) compared to mothers who were diagnosed negative for STIs.

Maternal seroprevalence was not significantly different in relation to residence, education level,to mother's occupation; being employed in child daycare or being health care worker (Table 3).

#### 191 Table 3. Unadjusted and adjusted associated factors of maternal CMV IgM seropositivity

#### 192 in Southern Ethiopia

Characteristics	Un adjusted		Adjusted	
	OR 95% CI)	P-value	OR (95% CI)	P-value
Age of mothers (years)				
<25	1		1	
25-29	1.5 (0.7 -3.2)	0.318	1.2 (0.4 – 4.0)	0.739
30- 35	1.5 (0.7 -3.2)	0.283	3.0 (1.0 – 9.0)	0.048
>35	3.2 (1.2–9.1)	0.026	4.9 (1.0 – 23.4)	0.047
Marital status				
Married	1		1	
Currently unmarried	2.2 (1.1 -4.3)	0.030	3.8 (1.3 -11.2)	0.015
Residence				
Urban	2.5 (1.0 -6.3)	0.064	2.3 (0.7 -7.9)	0.171
Rural	1		1	
Daycare worker				
Yes	2.1 (0.8 -5.3)	0.110	1.1 (0.2-5.4)	0.857
No	1		1	
Health care worker				
Yes	2.8 (1.1 - 7.2)	0.031	1.2 (0.2 – 7.4)	0.841
no	1		1	
Education				
Primary and below	0.6 (0.3 -1.1)	0.111	0.7 (0.3 -1.8)	0.475
Secondary and above	1		1	
Gestational age				
Term	1		1	

Preterm	3.5 (1.8 – 7.1)	< 0.001	3.9 (1.5 -10.3)	< 0.006
Daycare or Nursery school baby				
Yes	2.4 (1.3 – 4.5)	0.004	2.7 (1.1 – 6.4)	0.027
no	1		1	
Sharing a cup with children				
Yes	2.0 (1.1 – 3.8)	0.044	2.2 (0.9 – 5.4)	0.074
no	1			
Any of curable STIs (n=350)				
Yes	3.4 (1.5-7.8)	0.004	4.1 (1.6- 10.6)	0.003
No	1			

193

# 194 Discussion

In this study an overall 8.2% CMV IgM and 88.7% seroprevalence of CMV IgG were detected among pregnant women in southern Ethiopia. The associated factors of seropositivity were age, marital status, the presence of a curable STIs and sharing a cup with children. A statistically significant association was also observed between CMV seropositivity and preterm delivery.

The reported seropositivity of 88.6% CMV IgG in this study was comparable to a previous report of 88.5% h in central Ethiopia but a substantially higher rate (15.5%) of CMV IgM was detected in this study.(6) Seropositivity of CMV IgG in our study was in line with a review done in Africa, with ranges from 60% to 100%.(9) Seropositivity rates of 77.3% for IgG and 8.1% for IgM in Kenya,(7) 93% for IgG and 11.1% for IgM in Nigeria,(13) 94% for IgG and 8.5% for IgM in Tanzania(14) were comparable to our finding.

205 In our study seroprevalence of CMV IgM is in concordance with several African studies.(7, 13-206 15) However, our rate was higher when compared to 0.4% in Tanzania, (16) 2.5% in Sudan, (17), 207 and 7% in Egypt.(18) In the absence of maternal screening this high rate is alarming for policy 208 makers. By far developed countries pregnant women are screened for CMV because of the consequence for the fetus and newborn.(19, 20) However, in most developing countries 209 210 including Ethiopia, maternal CMV still lack awareness, overlooked and not diagnosed at least for 211 pregnant women.(21) The high rate of positive CMV IgM may not only reflect primary infection 212 but might also be attributed to reinfection or reactivation of CMV during pregnancy. So the 213 reported high seropositivity in this study point to the existing negligence and the need to start 214 screening to detect pregnant women at risk for congenital transmission of CMV.

In this study, elder age has significant association with seroprevalence. The same finding was reported in Sudan,(17) Kenya,(22), and Tanzania.(16) In addition a large scale study in London also reported that seropositivity increases with increasing age.(23) But, in a study in Egypt(18) and in Nigeria(24) age had no association with maternal CMV infection. The highest seroprevalence with age may indicate the more exposure of elders than youngsters or might be the existence of previous infection which can probably reactivated in the current pregnancy.

On the other hand, significant association of seroprevalence with having nursery schooled children among household was observed. For pregnant women the predictable source of CMV infection is young children mainly exposure to nursery schooled children.(25) Children easily get infected in school and frequently shed CMV in their saliva or urine for many years continuously where spreads readily in preschool setting.(26) This places seronegative pregnant women who have a young child in the home or in day care at increased risk of seroconversion.(27, 28) Susceptibility to acquisition of CMV infection is high possibly through the direct contact

with contagious secretions from their own children essentially in situation of poor hygienicpractice like in Ethiopia.(23)

Among candidate predictors for maternal CMV seropositivity, occupation like being health care worker, or child day care worker; being multigravida, lower educational level and having other children at home were not detected. However, significant association with women who delivered preterm was reported. Although, preterm delivery might be due to the effect of maternal CMV infection we can not to say the risk factor as there are a lot of other confounding factors for preterm.(29)

Likewise, seropositivity was found to be significantly associated with STIs detected at delivery 236 237 and currently being unmarried. Mothers who were positive for any of curable STIs had a four-238 time CMV seropositivity. It is also reported that STIs including CMV is more common in 239 unmarried pregnant women.(23, 25, 30) Although cytomegalovirus is a virus that is transmitted 240 through many body fluids, sexual transmission from a seropositive male partner is an additional 241 established route by which women may be infected with CMV.(31) Indeed, it is somehow 242 expected that sexual transmission is also responsible for reinfection of seropositive mothers with different virus strains in high-seroprevalence populations.(32) 243

The limitations of the present study are that we lack differentiation of CMV IgM positives of either primary or secondary (reinfection or reactivation) since we collected samples at the end of pregnancy and avidity test will not suitable. Moreover, it was a hospital-based study and not representative of all pregnant mothers in the locality since a significant portion of mothers may not deliver in the hospital. We lack also appropriate risk factors assessment tool as we mainly

focused on seroprevalence and nature of the enrolled participant (time of labour), hence more representative large scale survey is needed to identify possible risk factors prospectively.

# 252 Conclusion

In the present study, we documented a high rate of CMV seroprevalence among pregnant women in southern Ethiopia. The presence of a curable STIs, elder age, unmarried women, and having nursery schooled children have a significant association with seropositivity. Given that there is no existing CMV diagnostic facility, special attention should be designed for pregnant women in parallel to the existing antenatal care service. Besides, training health care professionals will support awareness conception for pregnant women concerning the sequels of CMV infection during pregnancy.

## 260 Acknowledgments

We thank the HU-CSH microbiology laboratory staffs for provision of all laboratory accommodations during sample processing and storage. We would like to recognise the study participants and a special thanks to midwife nurses at the obstetrics ward of the HU-CSH. Lastly, we want to express our thanks to VLIR-UOS for financial support.

Author Contributions: MH and EP contributed to the study design and conceptualisation. MH carried out the laboratory work. MH, EL, ZM and EP performed the statistical analysis and interpretation. All authors provided critical review and contributed to the write-up and approved the final version of the manuscript. MH had final responsibility to submit for publication. All authors read and amended drafts of the paper and approved the final version.

- **Funding**: No funding was obtained. But A PhD Scholarship supported by the research from the
- 271 Belgian Development Cooperation through the VLIR-UOS network program (University
- collaboration for better health in Ethiopia (UCBHE).
- 273 Competing interests: no competing interest
- 274 Patient consent: Obtained. All participants provided written, informed consent for study
- 275 participation.
- 276 **Ethics approval**: Ethical approval from all of the appropriate institutional review boards was
- obtained. The ethics review committee of Hawassa University (CMHS/283/2012), Jimma
- 278 University (IHRPGD/458/2020), National Health Research Ethics Review Committee
- 279 (SRA/14.1/ 144483/2020) Ethiopia, and Ghent University (PA2019-038/BC-08458) Belgium,
- approved the study.
- 281 **Data sharing statement**: No additional data are available.

### 282 References

- Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The "Silent" Global
   Burden of Congenital Cytomegalovirus. *Clinical microbiology reviews*. 2013;**26**(1):86-102.
   Nolan N, Halai UA, Regunath H, Smith L, Rojas-Moreno C, Salzer W. Primary
- cytomegalovirus infection in immunocompetent adults in the United States A case series. *IDCases*. 2017;**10**:123-6.
- 288 3. Lazzarotto T, Blázquez-Gamero D, Delforge M-L, Foulon I, Luck S, Modrow S, et al.
- 289 Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and
- 290 Management From a Panel of European Experts. *Frontiers in pediatrics*. 2020;**8**(13).
- Britt WJ. Maternal Immunity and the Natural History of Congenital Human
   Cytomegalovirus Infection. *Viruses*. 2018;**10**(8):405.
- 293 5. Mussi-Pinhata MM, Yamamoto AY. Natural History of Congenital Cytomegalovirus
- 294 Infection in Highly Seropositive Populations. *The Journal of infectious diseases.*
- 295 2020;**221**(Supplement\_1):S15-s22.
- 6. Mamuye Y BN, Delayehu B, Mekonen G Seroepidemiology study of CMV and Rubella
- among pregnant women at St. Paul's Hospital Millennium Medical College, Addis Ababa,
- Ethiopia . *Ethiop J Health Sciences*. 2016;**26**:427.

- Maingi Z, Nyamache AK. Seroprevalence of Cytomegalo Virus (CMV) among pregnant
  women in Thika, Kenya. *BMC research notes*. 2014;**7**:794-.
- 8. Khairi S, Intisar K, Enan K, Ishag M, Baraa A, Ali Y. Seroprevalence of cytomegalovirus
- infection among pregnant women at Omdurman Maternity Hospital, Sudan. Journal of Medical
   Laboratory and Diagnosis. 2013;4(4):45-9.
- 9. Mhandire D, Rowland-Jones S, Mhandire K, Kaba M, Dandara C. Epidemiology of
- Cytomegalovirus among pregnant women in Africa. *Journal of infection in developing countries*.
  2019;**13**(10):865-76.
- Bates M, Brantsaeter AB. Human cytomegalovirus (CMV) in Africa: a neglected but
   important pathogen. *Journal of virus eradication*. 2016;2(3):136-42.
- Ross SA, Fowler KB, Ashrith G, Stagno S, Britt WJ, Pass RF, et al. Hearing loss in
  children with congenital cytomegalovirus infection born to mothers with preexisting immunity. *The Journal of pediatrics*. 2006;**148**(3):332-6.
- 12. Bates M, Brantsaeter AB. Human cytomegalovirus (CMV) in Africa: a neglected but important pathogen. *Journal of virus eradication*. 2016;**2**(3):136-42.
- 13. Fowotade A, Okonko IO, Agbede OO, Suleiman ST. High seropositivity of IgG and IgM
- antibodies against cytomegalovirus (CMV) among HIV-1 seropositive patients in Ilorin, Nigeria.
   *African health sciences*. 2015;**15**(1):1-9.
- Ray K, Mahajan M. Seroprevalence of cytomegalovirus antibodies in patients attending
  STD and antenatal clinics. *J Commun Dis*. 1997;29(2):85-90.
- 319 15. Mhandire D, Duri K, Kaba M, Mhandire K, Musarurwa C, Chimusa E, et al.
- 320 Seroprevalence of Cytomegalovirus Infection Among HIV-Infected and HIV-Uninfected
- Pregnant Women Attending Antenatal Clinic in Harare, Zimbabwe. *Viral immunology*.
  2019;**32**(7):289-95.
- 16. Chibwe E, Mirambo MM, Kihunrwa A, Mshana SE. Magnitude of the Cytomegalovirus
- infection among pregnant women attending antenatal clinics in the city of Mwanza, Tanzania. BMC research notes 2017:10(1):489
- *BMC research notes*. 2017;**10**(1):489.
- Hamdan HZ, Abdelbagi IE, Nasser NM, Adam I. Seroprevalence of cytomegalovirus and
  rubella among pregnant women in western Sudan. *Virology journal*. 2011;8:217.
- 18. Kamel N, Metwally L, Gomaa N, Sayed Ahmed WA, Lotfi M, Younis S. Primary
- 329 cytomegalovirus infection in pregnant Egyptian women confirmed by cytomegalovirus IgG
- avidity testing. Medical principles and practice : *international journal of the Kuwait University*,
- 331 *Health Science Centre*. 2014;**23**(1):29-33.
- 19. Gyselaers W, Jonckheer P, Ahmadzai N, Ansari M, Carville S, Dworzynski K, et al.
- 333 What are the recommended clinical assessment and screening tests during pregnancy? Good
- Clinical Practice (GCP) Brussels: Belgian Health Care Knowledge Centre (KCE). 2015. KCE
- 335 Reports 248. KCE Reports. 2017;248.
- 336 20. Vaudry W, Rosychuk RJ, Lee BE, Cheung PY, Pang X, Preiksaitis JK. Congenital
- 337 cytomegalovirus infection in high-risk Canadian infants: Report of a pilot screening study. The
- 338 *Canadian journal of infectious diseases & medical microbiology* = Journal canadien des
- maladies infectieuses et de la microbiologie medicale. 2010;**21**(1):e12-9.
- 340 21. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection
- in the mother, fetus, and newborn infant. *Clinical microbiology reviews*. 2002;**15**(4):680-715.
- 342 22. Maingi Z, Nyamache AK. Seroprevalence of Cytomegalo Virus (CMV) among pregnant
- 343 women in Thika, Kenya. *BMC research notes*. 2014;**7**:794.

- 23. Tookey PA, Ades AE, Peckham CS. Cytomegalovirus prevalence in pregnant women: the influence of parity. Arabiyas of diagasa in abildhood, 1992;67(7, Spec No);770, 83
- the influence of parity. *Archives of disease in childhood*. 1992;**67**(7 Spec No):779-83.
- 24. Yeroh M, Aminu M, Musa B. Seroprevalence of cytomegalovirus infection amongst
- pregnant women in Kaduna state, Nigeria. *African Journal of Clinical and Experimental Microbiology*. 2015;**16**(1):37-44.
- 349 25. Fowler KB, Pass RF. Risk Factors for Congenital Cytomegalovirus Infection in the
- 350 Offspring of Young Women: Exposure to Young Children and Recent Onset of Sexual Activity.
- 351 *Pediatrics*. 2006;**118**(2):e286-e92.
- 26. Cannon MJ, Hyde TB, Schmid DS. Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection. *Rev Med Virol*. 2011;**21**(4):240-55.
- 27. Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection
- among parents of children attending day-care centers. *The New England journal of medicine*.
  1986;**314**(22):1414-8.
- 28. Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk
- factors: implications for congenital CMV. *Rev Med Virol*. 2010;**20**(5):311-26.
- 29. Pitlick MM, Orr K, Momany AM, McDonald EL, Murray JC, Ryckman KK.
- Determining the prevalence of cytomegalovirus infection in a cohort of preterm infants. *Journal of neonatal-perinatal medicine*. 2015;8(2):137-41.
- 362 30. Shakya S, Thingulstad S, Syversen U, Nordbø SA, Madhup S, Vaidya K, et al.
- Prevalence of Sexually Transmitted Infections among Married Women in Rural Nepal. *Infectious Diseases in Obstetrics and Gynecology*. 2018;2018:4980396.
- 365 31. Staras SA, Flanders WD, Dollard SC, Pass RF, McGowan JE, Jr., Cannon MJ. Influence
   366 of sexual activity on cytomegalovirus seroprevalence in the United States, 1988-1994. *Sexually* 367 *transmitted diseases*. 2008;**35**(5):472-9.
- 368 32. Adachi K, Xu J, Yeganeh N, Camarca M, Morgado MG, Watts DH, et al. Combined
- evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV
   transmission. *PloS one*. 2018;13(1):e0189851.
- 371

372

373